Kairos Pharma KAPA 深 沪
已收盘 08-21 16:00:00 美东时间
0.29
-0.005
-1.73%
华盛通- 最 高0.3014
- 今 开0.29
- 成交量 27.77万股
- 最 低 0.289
- 昨 收 0.2951
- 总市值 687.23万
- 52周最高 2.11
- 市盈率 静 --
- 换手率 1.17%
- 52周最低 0.2695
- 委 比 0.00%
- 总股本 2369.77万
- 历史最高 4.00
- 量 比 0.95
- 振 幅 4.20%
- 历史最低 0.2695
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kairos Pharma announces 1-for-7 reverse stock split to maintain NYSE compliance
Kairos Pharma (KAPA) announced on Friday that it will conduct a 1-for-7 reverse stock split effective September 1, 2026, before the market opens. The company’s shares will continue trading on the NYS...
08-22 04:38
Kairos Pharma Announces 1-For-7 Reverse Stock Split, Effective Sept. 1
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the "Reverse Stock Split"). The Reverse Stock Split is...
08-22 04:30
Kairos Pharma Partners With Bayer To Mull ENV-105 Inhibitor In Combination With Bayer’s XOFIGO
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in...
07-22 20:37
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?
Kairos Pharma, Ltd. (NYSE:KAPA) shares surged 22.64% to $0.39 in after-hours trading on Wednesday following the company’s announcement of positive interim safety data for its lead cancer drug candidate. The stock had closed down 6.47% at $0.32 during regular trading. Safety Data Fuels Investor Optim...
07-16 14:51
Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate
Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the same
04-01 06:37
Kairos Pharma Signs Deal To Acquire Two Experimental Lung Cancer Drug Candidates, Financial Terms Undisclosed
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn
02-26 20:14
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.
2025-11-04 22:30
